by admin | Jan 15, 2026 | News & Opinions
By Julie Grisham – Memorial Sloan Kettering Cancer Center – When it comes to giving immunotherapy to people with the most common form of lymphoma, the time of day may make a difference, according to new research from Memorial Sloan Kettering Cancer Center...
by admin | Jan 14, 2026 | News & Opinions
By Chinese Academy of Sciences – SciTechDaily – A new method for engineering natural killer cells could make cancer immunotherapy more efficient, scalable, and affordable, potentially reshaping how these treatments are produced. Chinese scientists have...
by admin | Jan 13, 2026 | News & Opinions
By Frank Vinluan – MedCity News – A rare but severe stem cell transplant complication that often becomes fatal now has its first FDA-approved treatment, a therapy developed by biotechnology company Omeros. Omeros’s complement system drug Yartemlea is now...
by admin | Jan 12, 2026 | News & Opinions
By Matt Hoffman – CGTlive – As 2025 comes to a close, CGTLive has looked back on some of the most-read and most impactful FDA regulatory decisions and news in the cell and gene therapy space. These approvals and regulatory actions marked major progress for...
by admin | Jan 9, 2026 | News & Opinions
By Genetic Engineering adn Biotechnology News – Cancer immunotherapy transforms a patient’s immune cells into a “search‑and‑destroy” force against tumors. But many cancers learn to camouflage themselves from dendritic cells—the immune system’s scouts—making them...
